NIMR Mbeya
Business Services · Tanzania · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Mbeya, Mbeya, TanzaniaPhone Number
+49 89218017601Website
www.mmrp.orgRevenue
$12 MillionIndustry
About NIMR Mbeya
NIMR Mbeya Org Chart
Is NIMR Mbeya your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NIMR Mbeya is spiking on competitors!
NIMR Mbeya, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when NIMR Mbeya launches new products
Earning: See what the market has to say on NIMR Mbeya recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at NIMR Mbeya
Check if NIMR Mbeya has recently received funding, and reach out quickly before it becomes old news!
Click to see if NIMR Mbeya had a recent Job posting/layoffs
Funding: Get notified immidiatlly once NIMR Mbeya has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at NIMR Mbeya
Find 2 more new buyers
Compare Similar Companies to NIMR Mbeya
Compare insights from companies similar to NIMR Mbeya, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NIMR Mbeya is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NIMR Mbeya is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NIMR Mbeya.
NIMR Mbeya Tech Stack
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding NIMR Mbeya
NIMR Mbeya conducts medical research on HIV/AIDS, Tuberculosis (TB), Ebola, Malaria and other relevant tropical diseases while evaluating clinical trials etc.... Read More